Две новости, как в анекдоте
.
Monthly supplementation with 60,000 IU of oral vitamin D3opens in a new tab or window for older adults didn't appear to increase or decrease overall fracture risk over a 5-year period. The same held true for non-vertebral, major osteoporotic, and hip fractures. (The Lancet Diabetes & Endocrinology)
Teprotumumab (Tepezza)opens in a new tab or window led to a significantly greater reduction in proptosis over placebo in people with chronic thyroid eye disease for an average of 5 years and low levels of disease activity (2.41 vs 0.92 mm, p=0.0004), Horizon announced with its phase IV trial results.
|